FOLH1 and prostate cancer: Lutetium Lu 177 vipivotide tetraxetan (3) is a radioligand that strongly binds to PSMA, making it ideal for treating prostate cancer through targeted radiation, which results in DNA damage and cell death.[47, 48] The synthesis process for PSMA‐617 (29) (Scheme 3) involves the use of solid‐phase peptide chemistry.